DAPA-HF, with Mikhail Kosiborod, MD

Podcast

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

Episode highlights

0:11 Intro
0:54 The SGLT-2 inhibitor class
2:40 The DAPA-HF Study
4:40 Mikhail Kosiborod, MD
37:37 Outro

About DAPA-HF

Published: November 21, 2019

Design: Phase 3, placebo-controlled clinical trial

Population: 4744 patients with HFrEF

Assessment: 10 mg daily dapagliflozin versus placebo, plus recommended therapy, for the reduction of composite worsening heart failure or cardiovascular death

Findings: Reduced occurence composite outcomes among patients with HFrEF, regardless of diabetes status, with treatment of dapagliflozin over observed median 18.2 months

Interesting note: The patient population was unique from those used in prior SGLT-2 inhibitor trials, as their risks for heart failure hospitalization and/or cardiovascular-related death were considered high by baseline metrics

The impact: “I think the care of patients with heart failure is going to be changed completely as a result of it.”

The second episode of Heart Trials, the newest specialty podcast series from HCPLive, features a look into an agent from possibly the most dynamic drug class in all of cardiovascular care: SGLT-2 inhibitor dapagliflozin.

In this episode of the monthly cardiovascular research series, study author Mikhail Kosiborod, MD, director of Cardiometabolic Research at Saint Luke's Mid America Heart Institute, and professor of Medicine at the University of Missouri-Kansas City, joins to discuss the DAPA-HF trial, as well as the application of dapagliflozin in COVID-19 patients with respiratory failure from the DARE-19 trial.

Attending ACC 2021? Share your thoughts on the meeting, and the state of cardiology, with our 2-minute survey!

Published in November 2019, DAPA-HF showed patients with established heart failure with reduced ejection fraction (HFrEF) with and without diabetes, benefitted from dapagliflozin in reduced risk of heart failure worsening or death form cardiovascular disease versus placebo.

The trial followed US Food and Drug Administration (FDA) application-supporting evidence of glycemic benefit among patients with diabetes given the SGLT-2 inhibitor—and preceded growing evidence of other cardiometabolic, cardiovascular, and renal outcome benefits among patients with heart disease.

Kosiborod joined to discuss the unique properties of the SGLT-2 inhibitor drug class, their potential ceiling in treating millions of at-risk Americans, the data which inspired DAPA-HF, and the lasting impact of his and his colleagues’ research.

Following DAPA-HF, Kosiborod turned attention to the DARE-19 trial, which he presented data for at the American College of Cardiology (ACC) 2021 Scientific Sessions this weekend.

Listen to Heart Trials on your favorite podcast platforms, including Spotify and Apple Podcasts.

Related Videos
Robert Wood, MD | Credit: LinkedIn
Marla Dubinsky, MD | Credit: LinkedIn
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Tom Nguyen, MD | Credit: Baptist Health
© 2024 MJH Life Sciences

All rights reserved.